These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9775441)

  • 1. 2-(3-Pyridyl)thiazolidine-4-carboxamide derivatives. II. Structure-activity relationships and active configuration of 2-(3-pyridyl)thiazolidine-4-carboxamides as platelet-activating factor receptor antagonists.
    Suzuki T; Nagaoka H; Kondo Y; Takahashi T; Takeuchi M; Hara H; Saito M; Yamada T; Tomioka K; Hamada M; Mase T
    Chem Pharm Bull (Tokyo); 1998 Sep; 46(9):1468-73. PubMed ID: 9775441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel orally active antagonists of platelet-activating factor (PAF).
    Nagaoka H; Hara H; Suzuki T; Takahashi T; Takeuchi M; Matsuhisa A; Saito M; Yamada T; Tomioka K; Mase T
    Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1659-64. PubMed ID: 9353894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-(3-Pyridyl)thiazolidine-4-carboxamide derivatives. III.) Synthesis of metabolites and metabolism of 2-(3-pyridyl)thiazolidine-4-carboxamides YM461 and YM264 as platelet-activating factor (PAF) receptor antagonists.
    Suzuki T; Nagaoka H; Hara H; Takeuchi M; Saito M; Yamada T; Tomioka K; Matsumoto H; Takanuki K; Mase T
    Chem Pharm Bull (Tokyo); 1999 Feb; 47(2):165-70. PubMed ID: 10071851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
    Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
    Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
    Koike H; Imanishi N; Natsume Y; Morooka S
    Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E; Heymans F; Redeuilh C; Batt JP; Massicot F; Blavet N; Braquet P; Godfroid JJ
    J Lipid Mediat; 1992 Feb; 5(1):23-40. PubMed ID: 1449553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
    J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Itoh K; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):541-50. PubMed ID: 8004699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ; Bull DJ; Cooper K; Parry MJ; Stefaniak MH
    J Med Chem; 1995 Sep; 38(18):3524-35. PubMed ID: 7658439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ex-vivo PAF-induced platelet aggregation by the PAF-antagonist RP 48740: relationship to plasma concentrations in healthy volunteers.
    Pinquier JL; Sedivy P; Bruno R; Bompart F; Gregoire J; Strauch G; Gaillot J; Clucas A
    Eur J Clin Pharmacol; 1991; 41(2):141-5. PubMed ID: 1743246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antagonists of platelet-activating factor. 1. Synthesis and structure-activity relationships of benzodiazepine and benzazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ; Cooper K; Parry MJ; Richardson K; Steele J
    J Med Chem; 1995 Sep; 38(18):3514-23. PubMed ID: 7658438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and platelet-activating factor (PAF)-antagonistic activities of trisubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):551-9. PubMed ID: 8004700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K; Fray MJ; Parry MJ; Richardson K; Steele J
    J Med Chem; 1992 Aug; 35(17):3115-29. PubMed ID: 1507200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
    Lamouri A; Heymans F; Tavet F; Dive G; Batt JP; Blavet N; Braquet P; Godfroid JJ
    J Med Chem; 1993 Apr; 36(8):990-1000. PubMed ID: 8478911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel class of platelet activating factor (PAF) antagonists. I. Synthesis and structure-activity studies on PAF-sulfonamide isosteres.
    Tsuri T; Haga N; Matsui T; Kamata S; Kakushi H; Uchida K
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):75-84. PubMed ID: 1605805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of plasma protein content and platelet number on the potency of PAF and its antagonist RP 59227 in rabbit platelet preparations.
    Floch A; Cavero I
    Br J Pharmacol; 1990 May; 100(1):163-7. PubMed ID: 2372657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAF inhibitory activity of diketopiperazines: structure-activity relationships.
    Shimazaki N; Shima I; Okamoto M; Yoshida K; Hemmi K; Hashimoto M
    Lipids; 1991 Dec; 26(12):1175-8. PubMed ID: 1819704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of novel thiazolidine derivatives as thromboxane A2 receptor antagonists.
    Sato M; Kawashima Y; Goto J; Yamane Y; Chiba Y; Jinno S; Satake M; Imanishi T; Iwata C
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):521-9. PubMed ID: 8004696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
    Serradji N; Bensaid O; Martin M; Kan E; Dereuddre-Bosquet N; Redeuilh C; Huet J; Heymans F; Lamouri A; Clayette P; Dong CZ; Dormont D; Godfroid JJ
    J Med Chem; 2000 Jun; 43(11):2149-54. PubMed ID: 10841793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.